TAIPEI, TAIWAN, 17 November 2026 — Early in his career, Dr. Cheng-Ta Li went looking for advice about magnetic brain stimulation and was told by a senior psychiatrist that the research had probably already reached its limits. He tried it anyway. Today Dr. Li, who directs the Precision Depression Intervention Center (PreDIC) at Taipei Veterans General Hospital and holds an appointment at the School of Medicine of National Yang Ming Chiao Tung University, wants psychiatry to stop treating "treatment-resistant depression" as a simple yes-or-no label. Resistance, in his view, is not a wall. It is a road, and patients stand at different points along it.
Opened in June 2022 as the first center in Taiwan devoted specifically to the precision assessment and treatment of depression, PreDIC has provided clinical services to more than 20,000 treatment-resistant depression (TRD) patient visits. Its signature tool, AI-PreDIC®, is a patented platform combining clinical information with biological measurements, including EEG and FDG-PET brain imaging, to give objective estimates of how severe a depression is and how stubbornly it has refused to yield. Consider the difference between a forecast that says only "storm" and one that reports wind speed, pressure, and the track of the eye.
"The key question in TRD is not simply whether a treatment works on average, but which treatment is most likely to help a particular patient at a particular stage of illness," Dr. Li says.
The Field He Almost Refused
Dr. Li was born in Taichung. As a medical student he wanted to know how everything worked: not only the brain but muscles, tendons, the whole humming machinery of the body. Psychiatry claimed him during clinical rotations, largely because so much of it remained unexplained. Then came the patients he could not forget, people with severe depression who had spent one or even two years in psychotherapy and conventional treatment, surrounded by families and clinicians who were doing everything right, and who still were not getting well.
When a mentor nudged him toward repetitive transcranial magnetic stimulation (rTMS), he hesitated, and the senior psychiatrist he consulted only deepened the doubt. He went ahead regardless. Some patients who had stayed depressed through prolonged treatment improved within a relatively short time, and what struck him most was not the lifting of mood but the way they began to see themselves, their circumstances, and their future. "Ironically, the field I was initially most reluctant to enter eventually became one of the defining themes of my career," he says.
He trained in functional neuroimaging, earned a PhD at the Institute of Brain Science under Professor Jen-Chuen Hsieh and Professor Tung-Ping Su, and completed a fellowship in the Molecular Imaging Branch of the U.S. National Institute of Mental Health with Professor Robert Innis. Back home he worked on brain stimulation and low-dose ketamine when both were still unfamiliar in clinical psychiatric settings. His 2014 study in the journal Brain was among the first large randomized sham-controlled trials of theta-burst stimulation for refractory depression, and he joined the effort to bring rTMS toward regulatory approval for depression in Taiwan. That slog taught him that evidence does not walk into a clinic by itself. It needs infrastructure, education, regulatory conversation, and people from different disciplines willing to share a table. That conviction lies behind both PreDIC and the Taiwanese Society of Brain Stimulation, of which he is founding President; the society held its first annual meeting in August 2026. He has also served as Secretary General of the Asian College of Neuropsychopharmacology and currently serves as a Councilor of the International College of Neuropsychopharmacology (CINP).
Treatment Resistance as a Continuum
His current work treats refractoriness as a continuum and asks how longitudinal biological adaptation might push a patient further along it. His group uses EEG, MRI, PET, and artificial intelligence to characterize depression, and population studies he coauthored have shown that TRD runs in families: in a 2024 JAMA Psychiatry analysis of national health insurance data for all of Taiwan, first-degree relatives of people with TRD were 9.16 times more likely to receive the diagnosis themselves. With more than 300 peer-reviewed publications to his name, Dr. Li has carried the science into patents, technology transfer, clinical consensus development, and professional training. He is also developing new treatments for difficult-to-treat mood disorders, from brain stimulation to emerging approaches such as psychedelics, and he wants the knowledge to leave the hospital through AI-based mental health chatbots, books, public lectures, and social media.
He is unsentimental about evidence. Findings, he argues, should be judged by how strong their evidence is, not by whether they were published or where they come from; exploratory studies and negative results matter, provided their limits are stated plainly. Asked to name his greatest fear, he gives an answer that doubles as a warning to his field: "Seeing patients place their trust in ineffective or unproven treatments and, as a result, miss the opportunity to receive appropriate care."
Curiosity, Evidence, and Michael Faraday
Asked about regrets, Dr. Li names one that is personal. "I wish I had understood more about mental health when my grandmother was still alive," he says. It is a reminder that distress can surface as physical complaints that are easy to overlook.
He is proud that financial gain has never been a major motivation in his career. Among his most treasured possessions are a government award plaque for scientific excellence and his family photographs. He plays badminton, hikes and travels with his family, admits a weakness for new electronic gadgets, and considers busyness for its own sake the most overrated virtue, because real progress usually needs time to reflect.
Given dinner with any historical figure, he would choose Michael Faraday, to ask how someone with very little formal education made so many discoveries in physics and chemistry. It is a fitting choice for a man once told his chosen field had nothing left to give, who decided to find out for himself. His motto is short: "Stay curious, question what you believe, and persist in what truly matters."
Dr. Cheng-Ta Li's Genomic Press interview is part of a larger series called Innovators and Ideas that highlights the people behind today's most influential scientific breakthroughs. Each interview in the series offers a blend of cutting-edge research and personal reflections, providing readers with a comprehensive view of the scientists shaping the future. By combining a focus on professional achievements with personal insights, this interview style invites a richer narrative that both engages and educates readers. This format provides an ideal starting point for profiles that explore the scientist's impact on the field, while also touching on broader human themes. More information on the research leaders and rising stars featured in our Innovators and Ideas – Genomic Press Interview series can be found on our interview website: https://interviews.genomicpress.com/ .
The Genomic Press Interview in Brain Medicine titled "Cheng-Ta Li: Using AI to guide biology-informed precision therapeutics across the continuum of treatment resistance in depression," is freely available via Open Access, starting on 17 November 2026 in Brain Medicine at the following hyperlink: https://doi.org/10.61373/bm026k.0066 .
About Brain Medicine: Brain Medicine (ISSN: 2997-2639, online and 2997-2647, print) is a peer-reviewed medical research journal published by Genomic Press, New York. Brain Medicine is a new home for the cross-disciplinary pathway from innovation in fundamental neuroscience to translational initiatives in brain medicine. The journal's scope includes the underlying science, causes, outcomes, treatments, and societal impact of brain disorders, across all clinical disciplines and their interface.
Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/
Our media website is at: https://media.genomicpress.com/
Our full website is at: https://genomicpress.com/